MedTrace Logo

An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Ribavirin Based Regimens in Patients With Chronic Hepatitis C With Previous Treatment Failure

NCT01798576 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 282

Last updated 2016-09-15

No results posted yet for this study

Summary

This prospective, national, multicenter, observational study will evaluate in routine clinical practice the efficacy and safety of re-treatment with Pegasys (peginterferon alfa-2a) plus ribavirin or regimens containing direct-acting antivirals in participants with chronic hepatitis C who failed previous treatment. Participants will be followed for the duration of their treatment (24, 48 or 72 weeks) and for 24 weeks of follow-up.

Conditions

  • Hepatitis C, Chronic

Interventions

DRUG

Pegylated Interferon alfa-2a

Dosing was at the discretion of the investigator in accordance with local clinical practice and local labelling.

DRUG

Ribavirin

Dosing was at the discretion of the investigator in accordance with local clinical practice and local labelling.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2015-06-30
Completion
2015-06-30

Countries

  • Romania

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01798576 on ClinicalTrials.gov